semaglutide compound nausea SkinnyRx SkinnyRx | Compounded Injectable Semaglutide
Description
Similarly, the European Medicines Agency (EMA) has not listed retatrutide as a medicine under active evaluation for marketing authorisation
The most common side effects during initiation are gastrointestinal, including nausea, vomiting, and diarrhoea, which are generally dose-dependent and transient
Individual variation depends on how long the medication was used, final dose level, and underlying metabolic health
The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants
